Research notes

Stay informed with the most recent market and company research insights.

A man sitting at a table with a glass of orange juice.

Research Notes

International Spotlight

Vertex Pharmaceuticals Inc
3:27pm
June 3, 2025
Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious and life-threatening diseases. Founded in 1989 in Cambridge, Massachusetts, the corporate headquarters is now located in Boston’s Innovation District, with the international headquarters in London, United Kingdom. Currently, Vertex has approximately 3,500 employees in the United States, Europe, Canada, Australia and Latin America with nearly two-thirds of staff dedicated to research and development. Vertex is recognised as one of the industry’s top places to work by Science Magazine, The Boston Globe, Boston Business Journal and the San Diego Business Journal. Vertex’s research and medicines have also received esteemed recognitions, including the Robert J. Beall Therapeutics Development Award, the French Prix Galien and the British Pharmacological Society awards.

Revising the plan

IDP Education
3:27pm
June 3, 2025
Further earnings pressure for IEL wasn’t surprising given the macro, however the quantum of IEL’s downgrade was significant. Implied 2H25 EBIT guidance of ~A$27m (mid-point) missed IEL’s quasi guidance set in Feb-25 of >A$77m. Synchronised immigration policy tightening continues to impact. IEL noted policy certainty and positive government rhetoric towards the sector is required to improve student flows. Both these look unlikely into the typically stronger 1H intake. IEL will implement cost, productivity and reduced investment measures in FY26 to offset anticipated ongoing industry volume pressures into FY26. IEL’s near-term earnings outlook is uncertain, with a relatively wide range of outcomes. Despite the significant de-rate, we think more earnings certainty is required and we move to a HOLD recommendation. Our valuation is A$6.50ps (DCF); however we set our price target at A$4.15ps (~17x FY26F EPS) to align our fundamental view (neutral until more earnings certainty achieved) to our recommendation structure (<10% TSR).

Don't throw the baby out with the bathwater

Treasury Wine Estates
3:27pm
June 3, 2025
A deceleration of US Premium wine sales (particularly 19 Crimes) below US$15 per bottle, has seen TWE revise its FY25 EBITS guidance. The downgrade was minor at 1.3% and better than feared. TWE’s Luxury portfolios appear to be performing well. However, focus is now on what impact a change in distributor in TWE’s key US market, declining Premium US wine sales and the tariffs will have on FY26. We have revised our forecasts. While not without risk given industry and macro headwinds, TWE’s trading multiples look far too cheap (FY25 PE of only 14.2x) and we maintain a BUY rating.

International Spotlight

Roche
3:27pm
June 3, 2025
Roche Holding AG is a Swiss multinational healthcare company that operates worldwide under two divisions: Pharmaceuticals and Diagnostics. Roche Pharma is focused on finding new medicines and diagnostics that help patients and evolve the practice of medicine. It treats ~28m people with its medicines and has 32 products on the WHO list of essential medicines. Roche Diagnostics develops diagnostics tests, instruments and digital solutions. This enables the collection of data, generating accurate and high-quality information that is used to inform clinical diseases around infections.

Consolidating with a strong balance sheet position

Earlypay
3:27pm
June 2, 2025
EPY recently provided a trading update and revised guidance. FY25 underlying NPATA is now expected at ~A$5m, from previous guidance of ~A$6m. The group is well capitalised, with no corporate debt and an expected surplus capital level of A$8m by FY25-end. Recently, listed consumer finance business Solvar (SVR) acquired a 19.9% strategic stake in EPY (acquired from COG Financial). SVR stated that the investment aligns with the group’s strategy, providing finance to underserviced markets. Whilst SVR’s ownership intentions are unknown (owning a strategic stake to pursue commercial outcomes or full ownership in time), industry partnerships and/or corporate appeal upside exists in the EPY investment case.

Sell-side roundtable

APA Group
3:27pm
June 2, 2025
We attended a sell-side analyst roundtable with management in Brisbane, which included a tour of APA’s operations centre that controls the bulk of APA’s assets. We recommend clients TRIM into current share price strength. We think the market’s focus will in time again be drawn to APA’s very material earnings and cashflow decline coming in less than 10 years’ time, which provides a meaningful headwind for equity value uplift and DPS growth.

International Spotlight

NVIDIA Corp
3:27pm
June 2, 2025
NVIDIA Corporation is an American semiconductor company and a global manufacturer of high-end graphics processing units (GPUs). The company is based in California and has five operating segments: (1) Data Center, (2) Gaming, (3) Professional Visualisation, (4) Automotive, and (5) Original Equipment Manufacturer (OEM). As the engine of Artificial Intelligence (AI), NVIDIA is committed to accelerating the growth of generative AI, by recognising it as a new computing platform, like the PC, internet and mobile-cloud.

International Spotlight

Pfizer Inc.
3:27pm
June 2, 2025
Pfizer is a research based pharmaceutical company that focuses on drug discovery for human diseases. It has a global portfolio including medicines and vaccines, as well as many other health care products. Its top 10 medicines and vaccines include: Comirnaty, Paxlovid, Eliquis, Prevnar, Ibrance, Vyndaqel, Xeljanz, Xtandi, Enbrel and Inlyta. The company collaborates with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. It has key franchises in cardiovascular, infectious diseases, inflammatory conditions and vaccines.

International Spotlight

Johnson & Johnson
3:27pm
June 2, 2025
Johnson & Johnson is an American multinational pharmaceutical and medical technologies company head quartered in New Jersey. The company manufactures health care products and provides related services for the pharmaceutical and medical devices markets. It develops and sells prescription pharmaceuticals and medical technology worldwide.

International Spotlight

Diageo
3:27pm
June 2, 2025
Diageo Plc (Diageo) engages in the production and distribution of alcoholic beverages. It is the number one player in the global spirits category and owns 9 of the top 30 global brands. Its product portfolio consists of a diverse range of alcoholic beverages including scotch, beer, whiskey, rum, ready-to-drink (RTD) beverages, wine, gin and tequila. Its major brands include Johnnie Walker, Crown Royal, JeB, Buchanan's, Windsor and Bushmills whiskies, Smirnoff, Ciroc and Ketel One vodkas, Captain Morgan, Baileys, Don Julio, Tanqueray, and Guinness.

News & insights

In recent days, several people have asked for my updated view on the Federal Reserve and the Fed funds rate, as well as the outlook for the Australian cash rate. I thought I’d walk through our model for the Fed funds rate and explain our approach to the RBA’s cash rate.

In recent days, several people have asked for my updated view on the Federal Reserve and the Fed funds rate, as well as the outlook for the Australian cash rate. I thought I’d walk through our model for the Fed funds rate and explain our approach to the RBA’s cash rate.

It’s fascinating to look at the history of the current tightening cycle. The Fed began from a much higher base than the RBA, and in this cycle, they reached a peak rate of 535 basis points, compared to the RBA’s peak of 435 basis points. For context, in the previous tightening cycle, the RBA reached a peak of 485 basis points.

The reason the RBA was more cautious this time around is largely due to an agreement between Treasurer Jim Chalmers and the RBA. The goal was to implement rate increases that would not undo the employment gains made in the previous cycle. As a result, the RBA was far less aggressive in its approach to rate hikes.

This divergence in peak rates is important. Because the Australian cash rate peaked lower, the total room for rate cuts and the resulting stimulus to the economy is significantly smaller than in previous cycles.

The Fed, on the other hand, peaked at 535 basis points in August last year and began cutting rates shortly after. By the end of December, they had reduced the rate to 435 basis points, where it has remained since.

Recent U.S. labour market data shows a clear slowdown. Over the past 20 years, average annual employment growth in the U.S. has been around 1.6 percent, but this fell to 1.0 percent a few months ago and dropped further to 0.9 percent in the most recent data.

This suggests that while the Fed has successfully engineered a soft landing by slowing the economy, it now risks tipping into a hard landing if rates remain unchanged.

Fed Funds Rate Model Update

Our model for the Fed funds rate is based on three key variables: inflation, unemployment, and inflation expectations. While inflation has remained relatively stable, inflation expectations have declined significantly, alongside the drop in employment growth.

As a result, our updated model now estimates the Fed funds rate should be around 338 basis points, which is 92 basis points lower than the current rate of 435. This strongly suggests we are likely to see a 25 basis point cut at the Fed’s September 17 meeting.

There are two more Fed meetings scheduled for the remainder of the year, one in October and another on December 10. However, we will need to review the minutes from the September meeting before forming a view on whether further cuts are likely.

Australian Cash Rate Outlook

Turning to the Australian cash rate, as mentioned, the peak this cycle was lower than in the past, meaning the stimulatory effect of rate cuts is more limited.

We have already seen three rate cuts, and the key question now is whether there will be another at the RBA’s 4 November meeting.

This decision hinges entirely on the September quarter inflation data, which will be released on 29 October 2025.

The RBA’s strategy is guided by the concept of the real interest rate. Over the past 20 years, the average real rate has been around 0.85 percent. Assuming the RBA reaches its 2.5 percent inflation target, this implies a terminal cash rate of around 335 basis points. Once that level is reached, we expect it will mark the final rate cut of this cycle, unless inflation falls significantly further.

So, will we see a rate cut in November?

It all depends on the trimmed mean inflation figure for the September quarter. If it comes in at 2.5 percent or lower, we expect a rate cut. The June quarter trimmed mean was 2.7 percent, and the monthly July figure was 2.8 percent. If the September figure remains the same or rises, there will be no cut. Only a drop to 2.5 percent or below will trigger another move.

We will have a much clearer picture just a few days before Melbourne Cup Day.

Read more
The Wall Street Journal of 21 August 2025 carried an article which noted that Ether, a cryptocurrency long overshadowed by Bitcoin has surged in price in August

The Wall Street  Journal of 21 August 2025 carried an article which noted that Ether, a cryptocurrency long overshadowed by Bitcoin has surged in price in August.

The article noted that unlike Bitcoin, there was not a hard cap on Ether supply, but the digital token is increasingly used for transactions on Ethereum , a platform where developers build and operate applications that can be used to trade, lend and borrow digital currencies.

This is important  because of the passage on 18 July 2025 of the GENIUS act which creates the first regulatory framework for Stablecoins. Stablecoins are US Dollar pegged digital tokens. The Act requires  that  Stablecoins , are to be to be fully  backed by US Treasury Instruments  or other  US dollar assets .

The idea is that if Ethereum becomes part of the infrastructure of Stablecoins , Ether would then benefit from increased activity on the Ethereum platform.

Tokenized money market funds from Blackrock and other institutions already operate on the Ethereum network.

The Wall Street journal  article  goes on to note that activity on the Ethereum platform has already amounted to more than $US1.2  trillion this year ,compared with $960 million to the same period last year.

So today ,we thought it might be a good idea to try and work out what makes Bitcoin and Ether  go up and down.

As Nobel Prize winning economist  Paul Krugman once said "  Economists don't care if a Model works in practice ,as long as it works in theory" .  Our theoretical model might be thought as a "Margin Lending Model" . In such a model variations in Bitcoin are a function of variation in the value of the US stock market .

As the US stock market rises, then the amount of cash at margin available to buy Bitcoin also rises .

The reverse occurs when the US stock market goes down .

Our model of Bitcoin based on this theory is shown in Figure 1  .  We are surprised that this simple model explains 88% of monthly variation  in Bitcoin since the beginning of 2019.

Figure 1 - BTC

At the end of August  our model  told us that when Bitcoin was then valued at $US112,491 , that it was then overvalued by $US15,785 per token.

Modeling Ether is not so simple . Ether is a token but Ethereum is a business.  this makes the price of Either sensitive to variations in conditions in the US Corporate Debt Market.

Taking that into account as well as stock market strength, gives us a model for Ether which is shown in figure 2.


Figure 2- Ethereum


This model explains 70.1% of monthly variation since the beginning of 2019. Our model tells us that at the end of August, Ether at $US 4,378per token was $US 560 above our model estimate of $US3,818.00 . Ether is moderately overvalued.

So neither  Bitcoin nor Ether are cheap right now.

ETFs for each of Bitcoin and Ether are now available from your friendly local stockbroker .

But right now , our models tell us that neither of them is cheap!

Read more
Uncover insights from Jackson Hole: Jay Powell’s rate cut hints, Fed’s soft landing concerns, and dire demographic trends. Analysis by Morgans’ Chief Economist.


There is more to what happened at Jackson Hole than just the speech by Jay Powell.

In my talk last week ,I said that our model of the Fed funds rate stood at 3.65%. This is actually 70 basis points lower than the actual  level of 4.35%.

I also said that the Fed was successfully achieving a "soft landing" with employment growing at 1%. This was below the median level of employment growth  since 2004 of 1.6%.

Still , as I listened to Jay Powell Speak , I noted a sense of concern in his voice when he said that "The July employment report released earlier this month slowed to an average pace of only 35,000 average per month over the past three months, down from 168,000 per month during 2024. This slowdown is much larger than assessed just a month ago."

My interpretation of this is that Chair Powell may be concerned that the "soft landing " achieved by the Fed may be in danger of turning into a "hard landing". This suggested a rate cut of 25 basis points by the Fed at the next meeting on 17-18 September.

This would leave the Fed Funds rate at 4.1%. This would mean that the Fed Funds rate would still be 45 basis points higher than our model estimate of 3.65%. Hence the Fed Funds rate would remain "modestly restrictive."

Dire Demography?

Jackson Hole was actually a Fed Strategy meeting with many speakers in addition to Jay Powell.

Two speakers who followed on the  afternoon of his speech were Claudia Goldin, Professor at Harvard

and Chad Janis of Stanford Graduate Business School. They each gave foreboding presentations on the demography of developed economies.

Claudia Goldin spoke on "The Downside of Fertility".  She noted that birth rates in the Developed World are now generally  below replacement level. The Total Fertility rate is below 2 in France , the US and the UK.

It is dangerously low below 1.5 in Italy and Spain and below 1 in Korea. She observes that the age of first marriage of couples  in the US is now 7 years later than it was in the 1960's. This reduces  their child bearing years.

This paper was then followed by a discussion of it by Chad Janis of Stanford Graduate Business School. He noted that there is a profound difference between a future with a replacement rate of 2.2 kids per family , which he called  the "Expanding Cosmos"  with

•   Growing population leading to a growing number of researchers, leading to rising living standards  and Exponential growth in both living standards and population AND a replacement level of 1.9 kids per family which leads to  

•   Negative population growth , which he called "an Empty Planet " and the end of humanity

 as numbers of researchers declines and economic growth ceases.

Of course this seems all  very serious indeed .  Perhaps what this really means ,is that  if  we want to save the world , we should just relax and start having a lot more fun!!

Read more